AI-Driven De Novo Design of Peptide Binders & Therapeutics for ANY Target

Expertise & Offer: We are the Patrick Bryant Lab (SciLifeLab, Stockholm), specializing in state-of-the-art Generative AI for structural biology and molecular design. We offer a proven computational platform to de-risk and accelerate the early stages of drug discovery.

Our Unique Technology:

• Universal Binder Design: We use EvoBind and RareFold to design high-affinity peptide binders for any protein target solely from sequence information.

• Non-Canonical Amino Acids (NCAAs): Unlike standard tools, we incorporate NCAAs to create molecules with enhanced stability, specificity, and immune evasion—ideal for next-gen therapeutics.

• Complex Targets: Proven success in designing agonists/inhibitors for difficult targets like GPCRs, viral fusion proteins (HIV-1), and protein-protein interactions.

What We Bring to Your Consortium:

• In Silico Design Lead: We can lead Work Packages (WPs) focused on hit identification, lead optimization, and structural modelling.

• Rapid Prototyping: Drastically reduce the time from target identification to candidate testing.

• Validation: We bridge the gap between AI prediction and wet-lab validation.

Looking For: We are looking to join Horizon Europe Cluster 1 (Health) 2026 and IHI Call 12 consortia focusing on:

• Pandemic Preparedness: Design of novel antivirals/entry inhibitors (e.g., Flaviviridae).

• AMR: Design of antimicrobial peptides or alternative scaffolds.

• Personalised Medicine: Patient-specific therapeutic design.